CODEINE PHOSPHATE SYRUP

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

CODEINE PHOSPHATE

可用日期:

LABORATOIRE ATLAS INC

ATC代码:

R05DA04

INN（国际名称）:

CODEINE

剂量:

25MG

药物剂型:

SYRUP

组成:

CODEINE PHOSPHATE 25MG

给药途径:

ORAL

每包单位数:

500ML/2L

处方类型:

Narcotic (CDSA I)

治疗领域:

OPIATE AGONISTS

產品總結:

Active ingredient group (AIG) number: 0104398001; AHFS:

授权状态:

MARKETED

授权日期:

1986-12-18

产品特点

CODEINE PHOSPHATE SYRUP 5 mg/mL
Page 1 of 31
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
CODEINE PHOSPHATE SYRUP
CODEINE PHOSPHATE 5 MG/ML (ORAL SYRUP)
OPIOID ANALGESIC
Laboratoire Atlas Inc,
9600, boul. des Sciences,
Montréal, Québec, Canada,
H1J 3B6
Date of Initial Approval:
January 16, 2013
Date of Revision:
August 30, 2018
Submission Control No: 213737
CODEINE PHOSPHATE SYRUP 5 mg/mL
Page 2 of 31
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................. 4
1
INDICATIONS
...................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
.................................................................................................................
4
2
CONTRAINDICATIONS
...................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................ 5
4
DOSAGE AND ADMINISTRATION
..................................................................................
6
4.1
Dosing Considerations
............................................................................................
6
4.2
Recommended Dose and Dosage Adjustment
....................................................... 7
4.3
Administration
..........................................................................................................
8
4.4
Missed Dose
............................................................................................................
8
4.5
Disposal
...................................................................................................................
9
5
OVERDOSAGE
................................................................................................................
9
5.1
Symptoms:
.....................